Tamone is an impulsive and creative person. He also has a very versatile first name. He thrives on experience and refuses to settle for a life of comfort. He thrives on new challenges and enjoys the challenge of overcoming them. Tamone excels at sales work and dealing in the public. He can use his creativity to help others and is resourceful. This personality has its risks.
Tamoxifen (or Tamone) may cause side effects, such as nausea, vomiting or diarrhea. These drugs are effective in treating breast tumors. Tamoxifen Citrat is an oral drug that’s highly absorbable through the GI system. It is extensively metabolized by the liver and excreted through breast milk. Tamoxifen is not recommended in pregnant women and those who have other medical conditions.
Although the medications are well-recommended, they can also cause life-threatening side effects. Tamoxifen is primarily used for breast cancer treatment. However, it is not a preventive treatment for DCIS or any other breast diseases. Side effects include stroke, deep vein embolism, and pulmonary embolism. It may also increase the likelihood of developing a form or uterine cancer called Urometrium Sarcoma.
Tamoxifen has the most common side effect of thrombocytopenia or leukopenia. For monitoring blood levels, it is necessary to perform regular complete blood tests. Tamoxifen is known to increase the risk of hypercalcemia for women with breast cancer and bone metastatics. Hypercalcemia can be serious so patients must be carefully monitored.
Tamoxifen showed a positive effect of bone metabolism in animals. However, its estrogenic properties have not been fully determined. Fortunately, side effects caused by tamoxifen are largely reversible. Tamoxifen Citrate has low acute toxicities in all animal species. The acute oral dose 50 (LD50), for rats, is above 0.01 g/kg.
One third of women who are treated with tamoxifen will develop fatty liver. This is generally a benign condition but can lead to steatohepatitis. Fatty liver often develops within one- to two years. Elevated serum aminotransferase can indicate liver steatosis. Fatigued liver injuries can be self-limiting, and are rarely life-threatening.
Tamoxifen has other side effects, including anemia, thrombocytopenia, and leukopenia. These side effects may be more prevalent in cancer patients. These side effects, while rare, should not be a problem for you or anyone in your relationship. Consult a doctor immediately if these side effects occur. The WHO’s official list includes this drug for breast cancer.
Tamoxifen versus tamone was compared in an uncontrolled study. The study involved patients suffering from recurrent breast tumors. Results were published December 31, 1996. TAM1 versus TAM2 was randomly selected. Tamoxifen, which is prescribed for two-years, was followed by megestrol.acetate, for six-months. While the risk of breast carcinoma was lower when these drugs were combined, patients were advised that they continue to use them for at least 5 years.
Studies in the past have shown that tamoxifen can be resisted by cells that are resistant to it. The researchers used T47D parental and resistant cell lines as a reference. They grew them in DMEM and RPMI-1640 with 10% FCS, 1% penicillin/streptomycin, and 1% insulin. Tamoxifen resistance arises from mutations within the tamoxifen -resistant cell lines.
Tamoxifen and Tamone are both commonly prescribed for the treatment or prevention of breast cancer. The nonsteroidal drug inhibits breast estrogen production. It also blocks the breast cells’ absorption of estradiol. It can be used in adjuvant treatment and in the prevention of breast carcinoma in premenopausal woman. These drugs are also available for men with advanced forms of cancer.
A 37-yearold woman, who had undergone bilateral mastectomy surgery and reconstructive breast surgeries, was found to have elevated enzymes after receiving Tamoxifen therapy. She denied ever experiencing symptoms of liver disease throughout treatment and concealed these concerns until the cancer recurred. She was later diagnosed with hepatic fibrosis. The patient received a tamoxifen-citrate treatment for 2 years. Within nineteen days, she was completely symptomatic.